Read Summary

The health regulator on Thursday declined to approve a treatment from Y-mAbs Therapeutics for a rare form of nerve cancer in pediatric patients, dragging the company’s shares down 16% in extended trading.
Reuters Health Information

Print Friendly, PDF & Email